<DOC>
	<DOCNO>NCT00541047</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Androgens cause growth prostate cancer cell . Androgen deprivation therapy , goserelin , leuprolide , bicalutamide , may lessen amount androgen make body . Giving radiation therapy together androgen deprivation therapy may kill prostate cancer cell . PURPOSE : This randomized phase III trial study well give radiation therapy together androgen deprivation therapy work treat patient undergone surgery prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Androgen Deprivation Therapy Treating Patients Who Have Undergone Surgery Prostate Cancer ( RADICALS )</brief_title>
	<detailed_description>OBJECTIVES : - Assess timing radiotherapy use hormone therapy conjunction post-operative radiotherapy . - Determine impact radiotherapy general quality life , sexual function , urinary function , bowel function . - Determine impact duration hormone therapy general quality life sexual function . OUTLINE : This multicenter study . Patients require immediate radiotherapy ( RT ) assign arm I ; patient require immediate RT assign arm II . Patients need immediate post-operative radiotherapy uncertain undergo radiotherapy time randomization within 3 month surgery randomize 1 2 radiotherapy arm . - Arm I ( immediate RT ) : Within 2 month randomization , patient undergo radiotherapy prostate bed day , 5 day week , 4 ( 20 fraction total ) 6.5 week ( 33 fraction total ) . They may also undergo radiotherapy pelvic lymph node day , 5 day week , 4.5 week ( 23 fraction total ) investigator 's discretion . - Arm II ( early salvage RT case PSA failure ) : Within 2 month confirmation post-operative biochemical failure , patient undergo radiotherapy arm I . Patients undergo immediate RT patient eventually need early salvage RT undergo hormone therapy duration randomization administration post-operative radiotherapy . Patients randomize 1 3 hormone therapy arm . - Arm III ( hormone therapy ) : Patients receive hormone therapy . They receive post-operative RT alone describe arm I II . - Arm IV ( RT short-term hormone therapy ) : Beginning approximately 2 month prior start RT , patient receive hormone therapy 6 month . Hormone therapy* may comprise LHRH agonist ( gonadotrophin-releasing hormone analogue [ GnRHa ] [ e.g. , goserelin leuprolide acetate ] ) bicalutamide daily . - Arm V ( RT long-term hormone therapy ) : Beginning approximately 2 month prior start RT , patient receive hormone therapy 24 month . Hormone therapy* may comprise LHRH agonist ( gonadotrophin-releasing hormone analogue [ GnRHa ] [ e.g. , goserelin leuprolide acetate ] ) bicalutamide daily . NOTE : *For Canadian patient , hormonal therapy consist LHRH analog ( leuprolide acetate ) therapy . Treatment continue absence disease progression unacceptable toxicity . Quality life assess use self-administered questionnaire baseline 1 , 5 , 10 year randomization . Health economics information also collect via patient-administered questionnaire ( EQ-5D ) baseline 1 , 5 10 year randomization . After completion study treatment , patient follow 7 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis nonmetastatic adenocarcinoma prostate Must undergone radical prostatectomy Postoperative serum prostatespecific antigen ( PSA ) &lt; 0.4 ng/mL No postoperative biochemical failure , define EITHER two consecutive rise PSA final PSA &gt; 0.1 ng/mL OR three consecutive rise PSA ( patient undergo hormone therapy duration randomization ) Exclusion criterion : Known distant metastasis prostate cancer PSA &gt; 5 ng/mL time hormone randomization ( patient undergo hormone therapy duration randomization ) PATIENT CHARACTERISTICS : No active malignancy likely interfere protocol treatment followup PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Coenrollment trial permit , provide interfere outcome measure 5Î± reductase inhibitor , soya , selenium , vitamin E acceptable nontrial therapy Exclusion criterion : Prior hormone therapy Bilateral orchidectomy Prior pelvic radiotherapy Neoadjuvant treatment Other concurrent therapy prostate cancer ( e.g. , estrogens cytotoxic chemotherapy ) prior disease progression</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>sexual dysfunction</keyword>
	<keyword>urinary complication</keyword>
	<keyword>gastrointestinal complication</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>